Scott Baker, MD, MS

Professor, Department of Pediatrics
University of Washington
Attending Physician, Pediatric Hematology/Oncology and Bone Marrow Transplantation
Seattle Children's Hospital

Education:

University of Nebraska College of Medicine, Omaha, NE. Doctor of Medicine, 1983-1988
University of Minnesota Graduate School, Minneapolis, MN. Master of Science in Clinical Research, 1999-2002

Research Expertise:

Dr. Baker's research interests are in the acute and long term-effects of hematopoietic cell transplantation and are focused on the use of epidemiologic methods to study treatment related acute and long-term complications in survivors after hematopoietic stem cell transplant. This research forms the basis for his current grant support in which the incidence, risk factors, and characteristics of cardiac, pulmonary, renal, endocrine, reproductive late effects and quality of life outcomes in survivors are being studied. Additional studies are examining the “metabolic syndrome” and the early development of cardiovascular risk factors and diabetes in transplant survivors.

Clinical Expertise:

Dr. Baker’s area of clinical expertise includes late effects of cancer therapy, in particular in pediatric patients that have undergone hematopoietic stem cell transplantation. He also conducts clinical trials in hematopoietic cell transplantation for non-malignant hematologic diseases such as Fanconi Anemia, immune deficiencies, and histiocytic disorders such as Langerhans Cell Histiocytosis and hemophagocytic lymphohistiocytosis.

Current Studies:

Dr. Baker is the principal investigator for FHCRC and the Seattle Children’s Hospital for participation in the multi-institutional Childhood Cancer Survivor Study. This study has made a tremendous number of scientific discoveries regarding the long term outcomes in survivors after childhood cancer. Additional studies in cancer survivors are examining the impact of the integration of patient reported outcomes in the clinical care of cancer survivors and on the health outcomes and delivery of survivorship care to young adult cancer survivors. Dr. Baker also serves as the principal investigator for several HCT clinical trials, particularly for treatment of children with hemophagoytic lymphohistiocytosis (HLH), Langerhan’s Cell Histiocytosis (LCH) and Fanconi Anemia.  



file

Contact Information

Phone
(206) 667-5594
Fax
(206) 667-5899
Email
Additional contact

Mail Stop: D5-280